These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB. J Thorac Oncol; 2020 Jan; 15(1):120-124. PubMed ID: 31605799 [Abstract] [Full Text] [Related]
29. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer. Xie F, Zheng X, Mao X, Zhao R, Ye J, Zhang Y, Sun J. Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850 [Abstract] [Full Text] [Related]
30. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database. Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calvetti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, Malapelle U, Novello S, Pasello G, Tiseo M. ESMO Open; 2024 Sep; 9(9):103680. PubMed ID: 39214048 [Abstract] [Full Text] [Related]
35. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer. Szpechcinski A, Moes-Sosnowska J, Skronska P, Lechowicz U, Pelc M, Szolkowska M, Rudzinski P, Wojda E, Maszkowska-Kopij K, Langfort R, Orlowski T, Sliwinski P, Polaczek M, Chorostowska-Wynimko J. Int J Mol Sci; 2024 Jul 19; 25(14):. PubMed ID: 39063150 [Abstract] [Full Text] [Related]
36. Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR. Das R, Jakubowski MA, Spildener J, Cheng YW. Cancers (Basel); 2022 Oct 01; 14(19):. PubMed ID: 36230737 [Abstract] [Full Text] [Related]
37. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M. Oncotarget; 2017 Jun 27; 8(26):42428-42437. PubMed ID: 28418914 [Abstract] [Full Text] [Related]
38. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH, Li H, Pan Y, Chak WP, Ng CS, Mok TS, To KF. Clin Cancer Res; 2016 Jun 15; 22(12):3048-56. PubMed ID: 26847053 [Abstract] [Full Text] [Related]